Late-onset Pneumocystis jirovecii pneumonia (PJP) in patients with ANCA-associated vasculitis

Pneumocystis Pneumonia and the Rheumatologist: Which Patients Are At Risk and How Can PCP Be Prevented?

(2017) Rachel M. Wolfe et al.   Current Rheumatology Reports

EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis

(2016) M Yates et al.   ANNALS OF THE RHEUMATIC DISEASES

Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis

(2015) Andreas Kronbichler et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Adverse events and infectious burden, microbes and temporal outline from immunosuppressive therapy in antineutrophil cytoplasmic antibody-associated vasculitis with native renal function

(2015) JulieAnne G. McGregor et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Overview of the 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides

(2013) J. Charles Jennette   Clinical and Experimental Nephrology

A randomized trial of mycophenolate mofetil versus cyclophosphamide for remission induction of ANCA-associated vasculitis: “MYCYC”. On behalf of the European vasculitis study group

(2013) R. Jones et al.   PRESSE MEDICALE

Lymphopenia and Treatment-Related Infectious Complications in ANCA-Associated Vasculitis

(2012) R. Goupil et al.   Clinical Journal of the American Society of Nephrology

Colonization by Pneumocystis jirovecii and Its Role in Disease

(2012) A. Morris et al.   CLINICAL MICROBIOLOGY REVIEWS

Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up

(2011) Lorraine Harper et al.   ANNALS OF THE RHEUMATIC DISEASES

Long-term patient survival in ANCA-associated vasculitis

(2010) O. Flossmann et al.   ANNALS OF THE RHEUMATIC DISEASES

Risk factors for major infections in Wegener granulomatosis: analysis of 113 patients

(2008) C Charlier et al.   ANNALS OF THE RHEUMATIC DISEASES